PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sirolimus - Angiofibroma from tuberous sclerosis complex

PAD Profile : Sirolimus - Angiofibroma from tuberous sclerosis complex

Brand Names Include :
Hyftor

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Gel
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

No indications returned.

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
22 November 2023
Not Set

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

NICE are expected to publish guidance on this drug (date tbc) and this will be considered by the APC within 90 days of publication

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More